Collectively, specific FOXOs may differentially contribute to DLBCL disease progression, with FOXO1 and FOXO3 activity assisting in promoting DLBCL cell death and preventing resistance to targeted therapies. The gene discussed is FOXO3; the disease is diffuse large B-cell lymphoma.